Home Featured Page 73

Featured

Latest

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Q4 2025: Oregon Psilocybin Services Update

PT469 – Drug Policy in 2023: The FDA’s Guidance for Clinical...

Pα+ Psychedelic Bulletin #151: Psilocybin for BDII, ACNP Readouts, Methylone for...

PT468 – Personalized Medicine, Biohacking, and Reconnecting to the Source

BREAKING: MAPS PBC Files New Drug Application for MDMA-Assisted Therapy for...

PT467 – The Role of Religion, Psychedelic Chaplaincy, and Spiritual Care

Pα+ Library: Bifurcated Scheduling

PT466 – The Philosophy of Alfred North Whitehead: Understanding Reality and...

PT465 – Beta-carbolines, Haoma, and Syrian Rue: Rediscovering Ancestral Knowledge

From Stress Relief to Better Sleep: How Wearables Can Improve Psychedelic...

Navigating Psychedelic Spiritual Emergencies

EDITOR PICKS

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.